Pathological Angiogenesis

In 1971, Judah Folkman published the first hypothesis that tumor growth is angiogenesis dependent, thus paving the way to the development of anti-angiogenic therapy.

In 2004, the FDA approved the first anti-angiogenic drug for metastatic colon cancer therapy, a monoclonal antibody (bevacizumab) able to neutralize the activity of the most powerful pro-angiogenic growth factor, the vascular endothelial growth factor (VEGF).
In the same period, new reports highlighted the role of VEGF in the aberrant formation of new blood vessels in the wet form of age-related macular degeneration. This observation set forth the subsequent use of anti-VEGF drugs also for the therapy of this pathology and subsequently for macular oedema and diabetic retinopathy.